TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04643002: Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) -

Sponsor: Sanofi · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 258 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$8,521,590

Rescue Site Savings

+$5,615,610

Unlock Full NCT04643002 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04643002 Rescue Dossier →